Abstract

Research Article

The Impacts of Angiotensin Receptor Blockers (ARBs) or Angiotensin-Converting Enzyme Inhibitors (ACEIs) on Patients with Stereotactic Body Radiation Therapy (SBRT) for Early-Stage NSCLC

Saber A Amin, Morshed Alam, Bangchen Wang, Weining Zhen, Chi Lin, Apar Kishor Ganti, Vinicius Ernani, Alissa Marr, Tony JC Wang, Simon K Cheng, Michael Baine and Chi Zhang*

Published: 24 June, 2023 | Volume 7 - Issue 2 | Pages: 033-041

Purpose: Stereotactic body radiation therapy (SBRT) has emerged as an alternative to surgery for patients with inoperable early-stage non-small cell lung cancer (NSCLC). The majority of inoperable NSCLC patients are elderly and frequently have comorbidities including cardiovascular diseases for which they frequently receive angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs). The interactions of these medications with SBRT are not clear. The objective of the current study is to investigate the interaction of ARBs and ACEIs with SBRT for the outcomes of early-stage NSCLC. 
Methods and Materials: A retrospective chart review of patients treated with SBRT for Stage I and II NSCLC (AJCC 7th edition) at a single institution between 2006 and 2017 was conducted. Information on the use of ARBs, ACEIs, demographics, and tumor-related factors was collected. Kaplan-Meier and Cox proportional hazard analyses were performed to assess the impact of ARBs and ACEIs combined with SBRT respectively on the treatment outcomes of these patients. 
Results: In total, 116 patients were included in the study, among whom 38/116 (32.76%) received ACEIs, and 20/116 (17.24%) received ARBs. In the multivariable analysis, the use of ARBs, but not ACEIs, with SBRT, was significantly associated with the increased risk of dissemination (Hazard Ratio (HR): 2.97; CI: 1.40-6.27; p < 0.004) compared to SBRT without ARBs. The tumor size of > = 3 cm was associated with significantly decreased time to local failure and OS compared to tumor size <3cm. 
Conclusion: In the current retrospective study, the use of ARBs, in combination with SBRT, was associated with a significantly increased risk of disease dissemination in early-stage NSCLC compared to SBRT alone. The findings warrant further investigations on the concurrent use of ARBs, ACEIs, and other medicines used for chronic diseases with SBRT for early-stage NSCLC.

Read Full Article HTML DOI: 10.29328/journal.jro.1001050 Cite this Article Read Full Article PDF

References

  1. Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, Jemal A, Cho H, Anderson RN, Kohler BA, Eheman CR, Ward EM. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014 May 1;120(9):1290-314. doi: 10.1002/cncr.28509. Epub 2013 Dec 16. PMID: 24343171; PMCID: PMC3999205.
  2. Febbo JA, Gaddikeri RS, Shah PN. Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer: A Primer for Radiologists. Radiographics. 2018 Sep-Oct;38(5):1312-1336. doi: 10.1148/rg.2018170155. Epub 2018 Aug 3. PMID: 30074857.
  3. Sebastian NT, Xu-Welliver M, Williams TM. Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC): contemporary insights and advances. J Thorac Dis. 2018 Aug;10(Suppl 21):S2451-S2464. doi: 10.21037/jtd.2018.04.52. PMID: 30206491; PMCID: PMC6123192.
  4. Kastelijn EA, El Sharouni SY, Hofman FN, Van Putte BP, Monninkhof EM, Van Vulpen M, Schramel FM. Clinical Outcomes in Early-stage NSCLC Treated with Stereotactic Body Radiotherapy Versus Surgical Resection. Anticancer Res. 2015 Oct;35(10):5607-14. PMID: 26408733.
  5. Wisnivesky JP, Bonomi M, Henschke C, Iannuzzi M, McGinn T. Radiation therapy for the treatment of unresected stage I-II non-small cell lung cancer. Chest. 2005 Sep;128(3):1461-7. doi: 10.1378/chest.128.3.1461. PMID: 16162744.
  6. Cardia J, Calçada C, Pereira H. Treatment of lung cancer in the elderly: Influence of comorbidity on toxicity and survival. Rep Pract Oncol Radiother. 2011 Feb 23;16(2):45-8. doi: 10.1016/j.rpor.2011.01.001. PMID: 24376955; PMCID: PMC3863214.
  7. Palma D, Visser O, Lagerwaard FJ, Belderbos J, Slotman BJ, Senan S. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol. 2010 Dec 10;28(35):5153-9. doi: 10.1200/JCO.2010.30.0731. Epub 2010 Nov 1. PMID: 21041709.
  8. Timmerman RD, Paulus R, Pass HI, Gore EM, Edelman MJ, Galvin J, Straube WL, Nedzi LA, McGarry RC, Robinson CG, Schiff PB, Chang G, Loo BW Jr, Bradley JD, Choy H. Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial. JAMA Oncol. 2018 Sep 1;4(9):1263-1266. doi: 10.1001/jamaoncol.2018.1251. PMID: 29852037; PMCID: PMC6117102.
  9. Zheng X, Schipper M, Kidwell K, Lin J, Reddy R, Ren Y, Chang A, Lv F, Orringer M, Spring Kong FM. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):603-11. doi: 10.1016/j.ijrobp.2014.05.055. Epub 2014 Jul 19. PMID: 25052562.
  10. Shibamoto Y, Hashizume C, Baba F, Ayakawa S, Miyakawa A, Murai T, Takaoka T, Hattori Y, Asai R. Stereotactic body radiotherapy using a radiobiology-based regimen for stage I non-small-cell lung cancer: five-year mature results. J Thorac Oncol. 2015 Jun;10(6):960-4. doi: 10.1097/JTO.0000000000000525. PMID: 26001145.
  11. Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, Karasawa K, Hayakawa K, Niibe Y, Takai Y, Kimura T, Takeda A, Ouchi A, Hareyama M, Kokubo M, Kozuka T, Arimoto T, Hara R, Itami J, Araki T. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1352-8. doi: 10.1016/j.ijrobp.2009.07.1751. Epub 2010 Jul 16. PMID: 20638194.
  12. Aydiner A, Ciftci R, Sen F. Renin-Angiotensin system blockers may prolong survival of metastatic non-small cell lung cancer patients receiving erlotinib. Medicine (Baltimore). 2015 Jun;94(22):e887. doi: 10.1097/MD.0000000000000887. PMID: 26039117; PMCID: PMC4616356.
  13. Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol. 2009 Oct;135(10):1429-35. doi: 10.1007/s00432-009-0587-3. Epub 2009 Apr 28. PMID: 19399518.
  14. George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer. 2010 Nov;10(11):745-59. doi: 10.1038/nrc2945. Epub 2010 Oct 22. PMID: 20966920.
  15. Pinter M, Jain RK. Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Sci Transl Med. 2017 Oct 4;9(410):eaan5616. doi: 10.1126/scitranslmed.aan5616. PMID: 28978752; PMCID: PMC5928511.
  16. Miao L, Chen W, Zhou L, Wan H, Gao B, Feng Y. Impact of Angiotensin I-converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Survival of Patients with NSCLC. Sci Rep. 2016 Feb 17;6:21359. doi: 10.1038/srep21359. PMID: 26883083; PMCID: PMC4756359.
  17. Song T, Choi CH, Kim MK, Kim ML, Yun BS, Seong SJ. The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: a meta-analysis. Eur J Cancer Prev. 2017 Jan;26(1):78-85. doi: 10.1097/CEJ.0000000000000269. PMID: 27158979.
  18. Menter AR, Carroll NM, Sakoda LC, Delate T, Hornbrook MC, Jain RK, Kushi LH, Quinn VP, Ritzwoller DP. Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 Mar;18(2):189-197.e3. doi: 10.1016/j.cllc.2016.07.008. Epub 2016 Aug 20. PMID: 27637408; PMCID: PMC5424707.
  19. Linhai Zhu, Jian Xiao Qu, Zhaofei Pang. The impact of hypertension and renin-angiotensin system blockers on outcomes of lung cancer patients: A population-based retrospective cohort study. Int J Clin Exp Pathol. 2017; 10(4): 4818-4826.
  20. Wang N, Liu J, Wang W. The impact of renin-angiotensin system blockers on lung cancers prognosis: A prisma-compliant systematic review and meta-analysis. Allied J Med Res. 2017; 1(1): 28-34.
  21. Small W Jr, James JL, Moore TD, Fintel DJ, Lutz ST, Movsas B, Suntharalingam M, Garces YI, Ivker R, Moulder J, Pugh S, Berk LB. Utility of the ACE Inhibitor Captopril in Mitigating Radiation-associated Pulmonary Toxicity in Lung Cancer: Results From NRG Oncology RTOG 0123. Am J Clin Oncol. 2018 Apr;41(4):396-401. doi: 10.1097/COC.0000000000000289. PMID: 27100959; PMCID: PMC5073047.
  22. Alite F, Balasubramanian N, Adams W, Surucu M, Mescioglu I, Harkenrider MM. Decreased Risk of Radiation Pneumonitis With Coincident Concurrent Use of Angiotensin-converting Enzyme Inhibitors in Patients Receiving Lung Stereotactic Body Radiation Therapy. Am J Clin Oncol. 2018 Jun;41(6):576-580. doi: 10.1097/COC.0000000000000324. PMID: 27560156.
  23. Jugdutt BI. Valsartan in the treatment of heart attack survivors. Vasc Health Risk Manag. 2006;2(2):125-38. doi: 10.2147/vhrm.2006.2.2.125. PMID: 17319456; PMCID: PMC1993995.
  24. Munger MA. Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions. P T. 2011 Jan;36(1):22-40. PMID: 21386934; PMCID: PMC3046622.
  25. Dézsi CA. The Different Therapeutic Choices with ARBs. Which One to Give? When? Why? Am J Cardiovasc Drugs. 2016 Aug;16(4):255-266. doi: 10.1007/s40256-016-0165-4. PMID: 26940560; PMCID: PMC4947116.
  26. Ying L, Hofseth LJ. An emerging role for endothelial nitric oxide synthase in chronic inflammation and cancer. Cancer Res. 2007 Feb 15;67(4):1407-10. doi: 10.1158/0008-5472.CAN-06-2149. PMID: 17308075.
  27. Choudhari SK, Chaudhary M, Bagde S, Gadbail AR, Joshi V. Nitric oxide and cancer: a review. World J Surg Oncol. 2013 May 30;11:118. doi: 10.1186/1477-7819-11-118. PMID: 23718886; PMCID: PMC3669621.
  28. Markowitz J, Wang J, Vangundy Z, You J, Yildiz V, Yu L, Foote IP, Branson OE, Stiff AR, Brooks TR, Biesiadecki B, Olencki T, Tridandapani S, Freitas MA, Papenfuss T, Phelps MA, Carson WE. Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+T cells in cancer and measurement of STAT1 nitration. Sci Rep. 2017 Nov 13;7(1):15424. doi: 10.1038/s41598-017-14970-0. Erratum in: Sci Rep. 2018 Mar 6;8(1):4203. PMID: 29133913; PMCID: PMC5684213.
  29. Masri FA, Comhair SA, Koeck T, Xu W, Janocha A, Ghosh S, Dweik RA, Golish J, Kinter M, Stuehr DJ, Erzurum SC, Aulak KS. Abnormalities in nitric oxide and its derivatives in lung cancer. Am J Respir Crit Care Med. 2005 Sep 1;172(5):597-605. doi: 10.1164/rccm.200411-1523OC. Epub 2005 Jun 9. PMID: 15947282; PMCID: PMC2718532.
  30. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer. 2006 Jul;6(7):521-34. doi: 10.1038/nrc1910. PMID: 16794635.

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?